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2Abstract
Alpha-synuclein is the main component of Lewy bodies, a histopathological finding of
Parkinson’s disease. Prolyl oligopeptidase (PREP) is a serine protease that binds to α-synuclein
and accelerates its aggregation in vitro. PREP enzyme inhibitors have been shown to block the
α-synuclein aggregation process in vitro and in cellular models, and also to enhance the
clearance of α-synuclein aggregates in transgenic mouse models. Moreover, PREP inhibitors
have induced alterations in dopamine and metabolite levels, and dopamine transporter
immunoreactivity in the nigrostriatal tissue. In this study, we characterized the role of PREP in
the nigrostriatal dopaminergic and GABAergic systems of wild-type C57Bl/6 and PREP
knock-out mice, and the effects of PREP overexpression on these systems. Extracellular
concentration of dopamine and protein levels of phosphorylated dopamine transporter were
increased and dopamine reuptake was decreased in the striatum of PREP knock-out mice,
suggesting increased internalization of dopamine transporter from the presynaptic membrane.
Furthermore, PREP overexpression increased the level of dopamine transporters in the
nigrostriatal tissue but decreased phosphorylated dopamine transporters in the striatum in wild-
type mice. Our results suggest that PREP regulates the function of dopamine transporter,
possibly by controlling the phosphorylation and transport of dopamine transporter into the
striatum or synaptic membrane.
3Introduction
Prolyl oligopeptidase (PREP) is a highly conserved serine protease that hydrolyses proline-
containing peptides shorter than 30 amino acids at least in vitro and also has non-hydrolytic
functions [1,2]. In vitro, PREP cleaves many peptide hormones such as substance P,
thyrotropin-releasing hormone, arginine-vasopressin, bradykinin, and neurotensin [1]. Many
of these neuropeptides are related to Parkinson´s disease (PD), Alzheimer´s disease (AD) and
other neurodegenerative diseases, and alterations in the PREP enzyme activity has been
observed in the brain tissue of PD, AD, Lewy body dementia and Huntington´s disease patients
[3]. However, the role of PREP in neuropeptide cleavage in vivo, and the physiological
importance of PREP have remained unclear [4-6].
PREP is widely distributed in different tissues in mammalian body but the highest activity has
been measured in the brain. PREP localizes in GABAergic and cholinergic interneurons of the
thalamus and cortex, as well as in the GABAergic neurons of the nigrostriatal tract and also, in
lesser extent, in dopaminergic (DAergic) neurons [7-9]. PREP is mainly found in the cell
cytosol but it can also be localized in the nucleus and bound to the membranes [1,10].
Moreover, PREP has been shown to co-localize with α-synuclein (aSyn), which is the main
component of the Lewy bodies of PD, and tau aggregates and beta-amyloid plaques of AD in
the post mortem brain samples [11]. Earlier, it has been shown that PREP directly binds to
aSyn and accelerates its aggregation in cellular models [12,13]. A potent and specific PREP
inhibitor, KYP-2047,was able block the aggregation of aSyn and enhance the clearance of aSyn
aggregates in both aSyn overexpressing cell lines and in aSyn transgenic mice [12]. KYP-2047
also increased the concentrations of dopamine (DA) and its metabolites and decreased DA
transporter (DAT) immunoreactivity in the striatal tissue in wild-type mice and in aSyn
transgenic mice, suggesting that PREP might have a role in regulating the nigrostriatal DAergic
system [14]. Moreover, in the study by Jalkanen et al. [15] two PREP inhibitors, KYP-2047
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PREP in the nigrostriatal neurotransmitter systems has not been extensively studied.
Although the concentration of extracellular DA is predominantly regulated by diffusion, the
kinetics and the volume of extrasynaptic DA is mainly regulated by DAT [16]. DAT function
is regulated with several different mechanisms but the main regulator of internalization of DAT
is protein kinase C (PKC) mediated phosphorylation [17-19]. Changes in DAT function has
been connected to PD and other DA related diseases, and altered levels of DAT markers have
been found in the brain of PD patients [20]. Balance in DAT levels in synaptic cleft is crucial,
since increased DAT on cellular membrane can lead to the accelerated DA uptake, which in
turn leads to oxidative stress, terminal damage and DA-induced cellular apoptosis [21,22].
aSyn binds to DAT and regulates its localization and function by recruiting and stabilizing the
transporter on plasma membrane [22-24]. aSyn aggregation, the key player in cellular toxicity
in PD, may cause elevated striatal extracellular levels of DA observed in the aSyn
overexpressing mice [25]. Furthermore, aSyn aggregation has effect on DA packing and DAT
trafficking [26,27]. However, this has been mostly studied in vitro, whereas mechanisms in
vivo are poorly understood although they might be pivotal in the pathophysiology of PD and
other neurodegenerative diseases [28]. Previous findings indicate that the regulation of
DAergic system, DAT function and aSyn aggregation by modulating PREP functions might be
a potential drug target in synucleinopathies and in other neurodegenerative diseases [14].
However, the physiological role of PREP protein in the nigrostriatal GABAergic and DAergic
systems is still unclear, and needs to be clarified to further support development of the PREP
inhibitors as drug therapy for PD. In this study, we have characterized the role of PREP in the
nigrostriatal DAergic and GABAergic systems and its effect on DAT function by using PREP
inhibitors, PREP knock-out mice and local PREP overexpression. Our results revealed that
PREP regulates the DA level and uptake by affecting DAT trafficking in DAergic cells.
5Materials and methods
Reagents
The reagents were purchased from Sigma-Aldrich (MO, USA) if not otherwise specified.
Ethanol was purchased from Altia (Finland). The PREP inhibitor, KYP-2047 (4-
phenylbutanoyl-l-prolyl-2(S)-cyanopyrrolidine), was synthesized in the School of Pharmacy,
University of Eastern Finland, as previously described by Jarho et al [29]. KYP-2047 has been
extensively characterized and the pharmacological and pharmacokinetic profile indicates that
it is highly selective, potent, and crosses the blood-brain barrier both in rats and mice [12, 14,
15, 30-32]. Adeno associated virus vectors (AAVs), AAV1-EF1α-hPREP (AAV-PREP) and
AAV1-EF1α-eGFP (AAV-GFP), were obtained from National Institute of Drug Abuse (Dr.
Brandon Harvey, Intramural Research Program, Baltimore MD, USA). Plasmid construction
was performed as described by Savolainen et al [14].
Animals
Male C57BL/6J mice (Wt) (7-9 weeks old; Envigo, The Netherlands) and PREP gene knock
out mice (PREP-KO) in C57BL/6JRccHsd genetic background (5–10 back crossings) were
used in this study [33, 34]. Deletion of exon 3 of the PREP gene was done as described by Di
Daniel et al [34]. Mice were housed under standard laboratory conditions (12 h light/dark cycle;
room temperature 23±2 °C; relative humidity: 50±15 %) in individually ventilated cages
(Mouse IVC Green Line, Techniplast, Italy) with bedding (Aspen chips 5 x 5 x 1 mm, 4HP,
Tapvei, Estonia), nesting material (Aspen strips, PM90L, Tapvei), and aspen brick (100 x 20
x 20 mm, Tapvei). Mice had access to chow food (Teklad 2016, Envigo, UK) and filtered and
irradiated water ad libitum. After surgical procedures, animals were individually housed for
the durations of the experiment. The experiments were carried out according to the European
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Animal Experiment Board.
Surgical procedures
Mice were anesthetized with isoflurane (4% induction, 1.5–2.0%maintenance; Attane vet 1000
mg/g, Piramal Healthcare, UK) and the recombinant AAV1 viral vectors were injected above the
substantia nigra (SN) in a stereotaxic operation. To target the SN, viral vectors were given as
a single injection (volume 1 µL, rate 0.2 µL/min) into the left hemisphere, 3.1 mm anterior and
1.2 mm lateral to bregma, and 4.2 mm below the dura (stereotaxic coordinates according to
Paxinos and Frankin [35]). Buprenorphine (0.1 mg/kg s.c.; Temgesic 0,3 mg/mL, Reckitt
Benckiser Healthcare, UK) was given before the operation, 12 h and 24 h after the surgery to
relieve post-operative pain. Guide cannula for microdialysis was inserted into the left striatum
at 0.6 mm anterior and 1.8 mm lateral, and 2.7 mm below the dura. The cannula was fastened
to the skull with dental cement (Aqualox, Voco, Germany) and two stainless steel screws (1.2
x 3 mm, DIN84, Helsingin Ruuvihankinta, Finland).
Characterization of viral vectors
To characterize the distribution and function of viral vectors, AAV1-EF1α-eGFP or AAV1-
EF1α-hPREP were injected unilaterally above the SN to Wt mice and the expression and
distribution was examined by immunohistochemistry 2 and 4 weeks post-injection. PREP
enzyme activity in the striatal tissue was measured 4 weeks post-injection. Detailed description
of PREP enzyme activity assay and immunohistochemistry can be found in the Supplementary
material (Fig. S1-2).
7Conventional microdialysis
Microdialysis was performed 5 weeks after the viral vector injections as described earlier [36].
A microdialysis probe (1-mm cuprophan membrane, o.d. 0.2 mm, 6 kDa cut-off; AT4.9.1.Cu,
AgnTho´s, Sweden) was inserted into the guide cannula 2 hours before the experiment and the
probe was perfused with a modified Ringer solution (147 mM NaCl, 1.2 mM CaCl2, 2.7 mM
KCl, 1.0 mMMgCl2, and 0.04 mM ascorbic acid) at the flow rate of 2.0 µL/min. Five baseline
samples were collected (20 min/40 µL/sample) after the stabilization period. After the
collection of baseline samples, the probe was perfused 2x20 min with 10 µM and 30 µM d-
amphetaminesulphate with 2x20min recovery time between the concentrations. The mice were
euthanized right after the microdialysis experiment by cervical dislocation followed by
decapitation. The brains were removed and rapidly frozen in isopentane on dry ice. The
concentrations of dopamine (DA), its metabolites, dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA) as well as gamma-
aminobutyric acid (GABA) in dialysates were measured using slightly modified versions of
the HPLC methods that have been described earlier [37,36]. Detailed description of the HPLC
systems can be found in the Supplementary material.
Similar microdialysis experiment was performed with PREP inhibitor administration in Wt
mice. After collecting baseline samples for 4x20 min, KYP-2047 or vehicle was injected
intraperitoneally and, thereafter, 15x20 min samples were collected. A repeated experiment
was carried out with the same mice after a 5-day treatment of KYP-2047 or vehicle. In the
repeated experiment, 9x20 min samples were collected after the stabilization period.
Amphetamine-induced DA release was measured in another set of mice. The mice received an
injection of KYP-2047 or vehicle after the collection of 4x20 min baseline samples and
8administration of amphetamine via probe (as described above) was started 3x20 min after the
injection.
No-net-flux microdialysis
No-net-flux microdialysis was performed with PREP-KO mice and Wt littermates. A
microdialysis probe (1-mm cuprophan membrane, o.d. 0.2 mm, 6 kDa cut-off; AT4.9.1.Cu,
AgnTho´s, Sweden) was inserted into the guide cannula 2 hours before the experiment and the
probe was perfused with a modified Ringer solution (147 mM NaCl, 1.2 mM CaCl2, 2.7 mM
KCl, 1.0 mM MgCl2, and 0.04 mM ascorbic acid) at the flow rate of 0.6 µL/min. Four
concentrations of DA in Ringer solution (Cin; 0, 2, 10 and 20 nM) were perfused through the
probes in a random order, and 3x30 min samples were collected at each Cin for HPLC analysis.
Linear equation was constructed for each animal by plotting the net flux of DA through the
probe (DAin - DAout) against DAin, where DAout is the dialysate DA concentration acquired
during the perfusion and DAin is the DA concentration of the perfusion fluid. Based on this
equation, the extracellular DA level (DAext) and the in vivo extraction fraction (Ed) was
calculated as described by Parsons and Justice [38]. The DAext value stands for the perfusion
fluid DA concentration at which there is no-net-flux of DA through the probe (DAin - DAout =
0). Ed, on the other hand, has been shown to describe combined DAT, NET and uptake2
functions [39-42].
Tissue HPLC analysis
Striatal tissue samples were punched below the corpus callosum + 0.74 mm from the bregma
to 2 mm depth by using sample corer (i.d. of 2 mm) with a plunger (Stoelting Co, USA) on a
cryostat (Leica CM3050) and the samples from the SN were punched from a brain slice
(thickness 1-1.5 mm) – 2.8 mm from the bregma by using sample corer (i.d. of 1 mm) with a
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metabolites DOPAC and HVA, and 5-HIAA in the tissue were performed as described earlier
[43]. Detailed description of the HPLC equipment can be found in the Supplementary material.
The tissue concentrations of GABA and glutamate were analyzed with HPLC equipped with a
fluorescence detector. Detailed description of the HPLC system can be found in the
Supplementary material. Concentrations are calculated as nanograms per milligram of brain
tissue.
Western blotting
Frozen tissue was homogenized with an ultrasound sonicator (GM35-400, Rinco Ultrasonic,
Switzerland) in 5 volumes of ice cold modified RIPA buffer (50 mM Tris HCl pH 7.4, 1% NP-
40, 0.25% sodium deoxycholate, 150 mM NaCl) containing Halt Phosphatase Inhibitor
(Product# 87786, Thermo Fisher Scientific, IL, USA) and Halt Protease Inhibitor cocktail
(Product# 78430, Thermo Fisher Scientific). After centrifuging at 16,000 g and 4°C for 15 min,
the supernatants were collected. Protein concentration was measured by the BCA method
(Thermo Fisher Scientific). For SDS-PAGE, 30 µg of protein was loaded onto a 4-20% Mini-
PROTEAN TGX precast gel (Product # 4561094, Bio-Rad, CA, USA). Gel was transferred to
nitrocellulose membrane (Trans-blot Turbo, Product# 1704158, Bio-Rad) by using Trans-blot
Turbo Transfer System (Bio-Rad). The membranes were blocked by 5% skim milk. Western
blots for DAT, tyrosine hydroxylase (TH) and beta-actin were done with SNAP i.d. 2.0 protein
detection system (Merck Millipore, MA, USA), except phospho (T53)-DAT that was done by
incubating the membrane with primary antibody overnight at +4 °C and thereafter with
secondary antibody for 2 h at room temperature. Following primary antibodies and dilutions
were used: DAT, rabbit anti-DAT (#PA1-4656, Thermo Fisher Scientific, dilution 1:1000 in
0.5% skim milk in 0.1% Tween-20 in tris-buffered saline (TTBS)); phospho (T53)-DAT
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(pDAT), rabbit anti-pDAT (#ab183486, AbCam, UK, dilution 1:500 in 5% skim milk in 0.05%
TTBS); TH, rabbit anti-TH (#ab153, Merck Millipore, dilution 1:2000 in 0.5% skim milk in
0.1% TTBS); beta-actin, rabbit anti-beta-actin (#4967S, Signalling Technology, MA, USA,
dilution 1:1000 in 0.5% skim milk in 0.1% TTBS). Goat anti-rabbit HRP was used for
secondary antibody for all the primary antibodies (#31460, Thermo Fisher Scientific, dilution
1:2000 in 0.5% skim milk in 0.1% TTBS). The images were captured with LI-COR C-digit
chemiluminescence scanner (LI-COR, Germany). Three independent WB experiments were
performed.
Optical density (OD) values of the WB images were analysed using ImageJ software (NIH,
MD, USA). The OD values were normalized to the loading control (beta-actin) OD’s.
Fast-scan cyclic voltammetry
Dopamine release was evoked on acute striatal slices of male mice (5-6 months of age) with
electrical stimulations and measured with a carbon fiber electrode calibrated with known
dopamine concentrations. The signal was amplified with Axopatch 200B amplifier (Molecular
Devices LLC, CA, USA), digitized (ITC-18 board; Instru-Tech, NY, USA) and analyzed with
a computer routine in IGOR Pro (WaveMetrics, OR, USA) as earlier described [44]. Detailed
description of fast-scan cyclic voltammetry can be found in the Supplementary material.
PREP inhibitor treatments
Wt mice received either the PREP inhibitor KYP-2047 (5 mg/kg) or vehicle twice a day
intraperitoneally (i.p.) for 5 days. KYP-2047 was diluted in 0.5% dimethylsulfoxide (DMSO)
in saline. Vehicle treatment groups received 0.5% DMSO in saline.
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Cylinder test
Cylinder test (cylinder height 15 cm, diameter 12 cm) was used to measure motor asymmetry
in spontaneous forelimb use after the unilateral microinjections [45,46]. Baseline paw
preference scores were acquired before the stereotaxic surgery, 2 weeks and 4 weeks post-
injection. In brief, mouse was filmed for 5 minutes. If the number of the individual rearing
episodes that resulted in the mouse touching cylinder wall was less than 10, the mouse was
excluded from the further analysis. Data was analyzed by a formula
஼௢௡௧௥௔௟௔௧௘௥௔௟ା଴.ହ∗஻௢௧௛
ூ௣௦௜௟௔௧௘௥௔௟ା஼௢௡௧௥௔௟௔௧௘௥௔௟ା஻௢௧௛
∗ 100; where ‘Both’ paws were defined as touches where animal
landed both of the forepaws simultaneously on the cylinder wall after the rearing. A non-
injected control mouse should score around 50% in this test. The animals were not allowed to
habituate to the testing cylinder before the video recording. The baseline level was set to 100
%; the results at 2 and 4 weeks were calculated as % of the baseline.
Locomotor activity test
The spontaneous locomotor activity of the AAV-transfected animals was measured before the
AAV-injections and 4 weeks after the injections and that of the PREP inhibitor-treated animals
was measured before the treatment and after a 5-day treatment with KYP-2047. At the
beginning of the lights-on period, the animals were placed in transparent cages (25 cm x 25 cm
x 15 cm, with food pellets and a water burette) with the activity monitor measuring infrared
beam interruptions (MED Associates, GA, USA). The measurement was started immediately
to record also the explorative behavior in a novel environment, and the data were collected at
15-min intervals for 20 hours.
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Statistical analysis
Statistical analysis was performed using either GraphPad Prism (version 6.02, GraphPad
Software, Inc., CA, USA) or SPSS Statistics (Version 22.0.0.1 IBM Corporation, NY, USA)
software. One- and two-way ANOVA with Bonferroni post-test and Student's t-test were used
as statistical tests. Data is presented as mean ± standard error of the mean (SEM). The results
were considered to be statistically significant at p < 0.05.
Results
Increased dopaminergic activity in the striatum of PREP knock-out mice
The impact of absence of PREP in the nigrostriatal DAergic and GABAergic systems was
examined in PREP-KO mice and their Wt littermates by striatal no-net-flux microdialysis to
measure the extracellular baseline level of DA, by conventional microdialysis to study the
amphetamine-induced DA release, and by tissue HPLC analysis to measure the concentration
of neurotransmitters and their metabolites in the striatal and SN tissue. The striatal extracellular
DA concentration was significantly increased in PREP-KO mice compared to Wt littermates
in no-net-flux microdialysis study (Fig. 1a; p = 0.036, Student´s t-test). The PREP-KO mice
had approximately 80 % higher concentration of extracellular DA in the striatum than their Wt
littermates. Additionally, the PREP-KO mice showed more pronounced amphetamine-induced
release of DA in the conventional microdialysis experiment (Fig. 2b, 10 µM amphetamine
(AMPH), genotype effect: F1,37 = 6.799, p = 0.013, 30 µM AMPH, genotype effect: F1,37 =
8.681, p = 0.006, repeated measures 2-way ANOVA). PREP-KO mice were also more active
during the exploratory phase in the locomotor activity test (Fig. S3a in the Supplementary
material, 0-60 min: F1,22 = 7.567, p = 0.012, repeated measures 2-way ANOVA). Tissue
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concentrations of DA, 5-HT, their metabolites, glutamate and GABA in the striatum and SN
were similar in both genotypes (Fig. 3).
Altered DAT phosphorylation and function in the PREP knock-out mice
The levels of DA-related proteins DAT and TH in the striatal and SN tissue were studied by
Western blotting, and DAT function was studied in acute striatal slices by fast-scan cyclic
voltammetry. PREP-KO and Wt mice had similar concentration of DAT in the nigrostriatal
tract (Fig. 4a-b) but the level of phosphorylated DAT was higher in the striatum of PREP-KO
mice (Fig. 4c; p = 0.0338, Student´s t-test). In addition, TH level was increased in the SN tissue
but not in the striatal tissue of PREP-KO mice (Fig. 4e-f; p = 0.0038, Student´s t-test). Several
parameters representing the DA release and reuptake dynamics were calculated from the single
pulse stimulation -evoked DA transients recorded with fast-scan cyclic voltammetry in acute
striatal slices. The efficacy of DA reuptake by DAT can be estimated from the half width of
the transients (the width of the transient at half maximum of the DA peak) as well as from the
fall time and tau values of the exponential decays of the transients [47]. The half widths (Fig.
1d, p = 0.0020, Student´s t-test) and values (Fig. 1e, p = 0.028, Student´s t-test) of DA peaks
were increased in the PREP-KO mice and there was a similar trend in the fall time (Fig 1f, p =
0.078, Student´s t-test) suggesting that the DA reuptake was delayed. The amount of DA
released by single pulses i.e. the peaks of the transients were slightly higher in PREP-KO mice
but there was no statistically significant difference (Fig. 1c, p = 0.356, Student´s t-test). The
recovery of the DA terminals from the preceding exocytosis in paired-pulse stimulations and
the amounts of DA released by burst stimulations were similar in the PREP-KO and Wt mice
(Fig. S4a-b in the Supplementary material). In addition, in slice recordings, in the dorsal striatal
area, the amphetamine-induced DAT reversal and DA release through DAT was unchanged
(Fig. S4c-d in the Supplementary material).
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Overexpression of PREP elevates the striatal DAT in wild-type mice
The effect of PREP overexpression in the nigrostriatal tract was studied by the striatal
microdialysis and tissue HPLC analysis, and the DA-related proteins DAT and TH were
studied by Western blotting. The behavioral effects caused by the unilateral nigral PREP
overexpression were studied by cylinder test and locomotor activity test. The nigrostriatal
overexpression of PREP by AAV-hPREP did not have an effect on the extracellular baseline
concentration of DA (Fig. 2a) and its metabolites (Fig. 2c-d) or amphetamine-induced release
of DA (Fig. 2b) but the baseline level of 5-HIAA (Fig.2e; p = 0.0048, Student´s t-test) and
GABA (Fig. 2f; p = 0.047, Student´s t-test) were elevated. Tissue concentrations of DA, 5-HT,
their metabolites, glutamate and GABA in the striatum were unchanged (Fig. 3) but DA in the
SN was elevated (Fig. 3h). Overexpression of PREP also increased the protein level of DAT
in the striatum (Fig. 5a; p = 0.027, Student´s t-test) and in the SN (Fig. 5b; p = 0.033, Student´s
t-test) measured by Western blotting. Moreover, phosphorylated DAT was decreased in the
striatum (Fig. 5c; p = 0.0281, Student´s t-test) but not in the SN (Fig. 5d). The amount of TH
was unchanged both in the striatum and SN (Fig. 5e-f). Unilateral PREP overexpression did
not have an effect on the locomotor activity (Fig. S3b in the Supplementary material) but AAV-
GFP decreased the use of the contralateral paw in the cylinder test (Fig. S5 in the
Supplementary material, baseline vs. 4 weeks, F2,32 = 3.547, *p = 0.044 ,1-way ANOVA,
Bonferroni post-test).
Restoring PREP protein to the substantia nigra of PREP knock-out mice increases the striatal
dopamine
PREP function was restored to PREP-KO mice by a nigral injection of AAV-hPREP, and the
nigrostriatal DAergic and GABAergic systems were studied 5 weeks post-injection by
conventional microdialysis and tissue HPLC analysis. Behavior was studied with cylinder test
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and locomotor activity test. Restoring the PREP function to the PREP-KO mice did not have
an effect on the extracellular concentration of DA, its metabolites or 5-HIAA (Fig. 2a, 2c-f)
but the striatal tissue concentration of DA was increased (Fig. 3a; p = 0.016, Student´s t-test).
Levels of DA-related proteins DAT, pDAT and TH were not changed (Fig. S6 in the
Supplementary material). Use of contralateral paw was increased in the mice that received an
AAV-hPREP injection (Fig. S5 in the Supplementary material, baseline vs. 4 weeks, F2,14 =
4.994, p = 0.029, 1-way ANOVA, Bonferroni post-test) but remained at the baseline level in
the AAV-GFP group. Restoring the PREP function did not have an effect on the locomotor
activity (Fig. S3c in the Supplementary material)
PREP inhibition induced alteration on the metabolites of dopamine in wild-type mice
PREP inhibition elevated concentration of DA in the striatum of A30P point-mutated
transgenic mice but not in the Wt mice in a previous study [14]. In addition, immunoreactivity
of DAT was increased in both Wt and transgenic mice. To study these observations further, we
examined the effect of acute and long-term PREP inhibition on the nigrostriatal DAergic and
GABAergic system by microdialysis, tissue HPLC analysis and Western blotting. The single
dose of PREP inhibitor, KYP-2047, did not have an effect on the extracellular baseline levels
of DA, its metabolites, GABA and 5-HIAA (Fig. S7 in the Supplementary material) or
amphetamine-induced release of DA (Fig. S8 in the Supplementary material) in the
microdialysis study but the 5-day treatment by KYP-2047 elevated HVA level (Fig. S7F in the
Supplementary material, p = 0.0359, Student´s t-test) and there was a similar trend in DOPAC
(Fig. S7d in the Supplementary material, p = 0.0774, Student´s t-test). Tissue concentration of
DA and 5-HT, their metabolites, GABA, glutamate, DAT, pDAT and TH in the striatum and
in the SN remained unchanged (Fig. S9 and Fig. S10 in the Supplementary material), and the
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PREP inhibition did not have an effect on the locomotor activity either (Fig. S3e-f in the
Supplementary material).
Discussion
In this study, we comprehensively studied the absence, restoration and overexpression of PREP
protein on the nigrostriatal pathway to reveal the role of PREP in the striatal and the nigral
DAergic and GABAergic system. In addition, the effect of acute and 5-day PREP inhibitor
treatment on the nigrostriatal neurotransmitter systems was studied. The most significant
finding was that the absence of PREP protein in the knock-out mice caused elevated
extracellular DA levels and impaired DAT function in the striatum, suggesting a role for PREP
in DAT internalization. To our knowledge, this is the first study where the role of PREP on
DAT function has been observed, and the overall importance of PREP protein for
neurotransmitter systems of the nigrostriatal pathway has been characterized.
In earlier studies, PREP expression has been detected in the nigrostriatal GABAergic neurons
and to some extent in DAergic neurons, and administration of PREP inhibitors has decreased
the extracellular DA in the rat striatum [15], and chronic PREP inhibitor treatment has
decreased DAT-immunoreactivity in the mouse striatal tissue [14]. However, the physiological
role of PREP protein in the nigrostriatal neurotransmission has remained unclear. In this study,
we found that the PREP-KO mice had higher concentrations of pDAT in the striatum. This
indicates that PREP-KO mice have more internalized DAT and less DAT on the presynaptic
membrane as phosphorylation is the main regulator of DAT internalization [17,19]. As DAT
can transport DA only when located on the cellular membrane, low concentrations of DAT on
the membrane cause impaired reuptake of DA, which was seen in the current study as higher
extracellular concentrations of DA in the no-net-flux microdialysis and as delayed reuptake of
DA in the fast-scan cyclic voltammetry measurements. Elevated amphetamine-induced release
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of DA in the conventional microdialysis experiment also further supports the altered DAT
function and DA reuptake in the PREP-KO mice. Amphetamine rapidly diminishes DAT
function by phosphorylation of DAT via PKC or oxidative inactivation leading to a massive
reduction of DA clearance in the extracellular space [48]. Reduced DAT function on the
presynaptic membranes of PREP-KO mouse leads to reduced reuptake and increased
extracellular DA that was seen in the microdialysis experiment. The high concentration of TH
in the SN can also explain the higher amount of the extracellular DA in the PREP-KO mouse
as TH is the rate limiting enzyme in DA synthesis [49].
Altered DAT function induced by absence or overexpression of PREP suggests that PREP has
an important role in the nigrostriatal DAergic system regulating the phosphorylation and
internalization of DAT. This was further supported by the overexpression studies, where we
detected increased level of DAT in the nigrostriatal tract and reduced pDAT in the striatum,
indicating that internalization of DAT is decreased and the level of DAT is elevated on the
cellular membrane. Interestingly, there were no statistically significant changes in the
extracellular or tissue concentration of DA in the striatum, indicating that the physiological
amount of PREP in DAergic neurons is sufficient to regulate DAT trafficking effectively.
However, PREP overexpression resulted in an increased levels of the extracellular GABA and
HVA in the striatum, and elevated tissue DA levels in the SN. Since this is the first time when
PREP has been connected to the DAT functions and trafficking, the mechanism behind this is
not yet known. PREP has been connected to cellular microtubule network, and trafficking and
secretion of proteins [10], which might link it to DAT trafficking and internalization. Other
possibility is that PREP regulates the phosphorylation of DAT via PKC or Jun-kinases but both
of these theories require further studies.
In addition, increased explorative behavior in locomotor activity test correlates with the
elevated DAergic activity in the nigrostriatal tract of PREP-KOmice. Locomotor hyperactivity
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of the PREP-KO mice has also been found in an earlier study [33] and acute PREP inhibition
has also resulted in increased explorative activity in rats [50], suggesting a role of PREP in
DA-regulated locomotor activity.
Restoring PREP function did not have an effect on the extracellular level of neurotransmitters
and their metabolites or DA related proteins indicating that the PREP-KO mice might have
some compensating mechanisms regulating DAergic system. However, the tissue
concentration of DA in the striatum was elevated which might indicate a normalized DA
function and might explain the increased use of contralateral paw in the cylinder test.
Intriguingly, AAV-GFP had a toxic effect on contralateral paw use in the Wt but not in PREP-
KO mice in the cylinder test, suggesting that the PREP-KO mice might have some
neuroprotective mechanisms against the protein overexpression. One possible mechanism for
this could be increased clearance of protein overload by cellular autophagy, as it has been
shown PREP to be a negative regulator of PI3K class III autophagy [14].
PREP inhibition has been shown to increase the striatal tissue concentration of DA in aged
A30P point-mutated transgenic mice but not in Wt mice [14] and to reduce extracellular DA
after acute dosing in rats [15]. In this study, we found that the 5-day treatment with PREP
inhibitor did not have an effect on the extracellular concentration of DA in either genotype but
the level of DA metabolites was increased in the Wt mice. Tissue concentration of DA and 5-
HT, their metabolites, GABA, glutamate or DAT was not changed. In the previous study [14],
the level of DA metabolites was increased in the striatal tissue. However, in that study the
samples were collected 32 hours after the last injection of KYP-2047 whereas in this study the
tissue samples were collected already 8 hours after the injections. The different time point
might explain the difference in the results. Additionally, we used young mice in this study
whereas mice aged 12 to 16 months were used in the previous study. In the earlier study, DAT
immunoreactivity in striatum was increased after the chronic PREP inhibition but we did not
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find any differences in the DAT in a Western blot analysis despite that the PREP
overexpression-induced the striatal DAT level. However, aging may cause the alteration in
DAT function, which might explain the difference between young mice in this study and aged
mice in the previous study [51-53]. Furthermore, we did not use long-term inhibition of PREP
in the present study. In contrast to the study by Jalkanen et al [15], we did not find any changes
in DA or metabolite levels following an acute PREP inhibitor injection but the dissimilarity
may be explained by a different dose of KYP-2047 (5 mg/kg vs. 17 mg/kg) and by the use of
different species.
In conclusion, our results show that (1) the absence and the overexpression of PREP causes
changes in phosphorylation of DAT, (2) the active site inhibitor KYP-2047 does not imitate
the lack of PREP expression, (3) the hyperactivity of PREP-KO mice is due to increased DA
action, and (4) the restoration of PREP function does not have effect on DAT indicating
compensative mechanisms in PREP-KO mice. The results suggest that PREP protein has a
remarkable role in the nigrostriatal DAergic system by regulating DAT trafficking or
internalization.
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Fig. 1 The PREP knock-out (KO) mice had higher extracellular concentrations of dopamine
(DA) in the striatum compared to the wild-type (Wt) littermates in the no-net-flux
microdialysis study (a). Fast-scan cyclic voltammetry recordings revealed a delayed DA
reuptake in the KO mice. The picture is showing the averaged and normalized single pulse
stimulation -evoked DA transients for both genotypes, to illustrate the delayed DA reuptake in
the KO mice (b). Heights of DA release peaks were slightly higher in KO mice but the
difference was not statistically significant (c). Half-width (d) and tau values (e) of DA
transients were longer in the KO mice and there was a similar trend in the fall time (f). a: n =
5-6, b-f: n = 13-14. Bars represent mean ± SEM, *p<0.05, **p<0.01, Student´s t-test.
Fig. 2 Extracellular striatal concentration of dopamine (DA), its main metabolites DOPAC and
HVA, 5-HIAA and GABA was measured in the wild-type (Wt) and PREP knock-out (KO)
mice by microdialysis 5 weeks after a supranigral injection of AAV-hPREP or AAV-GFP.
Overexpression of PREP did not have an effect on DA (a), DOPAC (c) or HVA (d) but the
concentration of 5-HIAA (e) and GABA (f) was increased (Student´s t-test). Restoring PREP
protein to the KO mice did not have an effect on the neurotransmitters or their metabolites.
AAV-hPREP did not have an effect on amphetamine (AMPH)-induced release of DA in either
of the mouse strains (b) but DA release was elevated in the KO mice compared to the Wt mice
with both concentrations of AMP, 10 µM 100-120 min and 30 µM 180-200 min (repeated
measures, 2-way ANOVA). Bars represent mean ± SEM, *p<0.05, **p<0.01.
Fig. 3Wild-type (Wt) and PREP knock-out (KO) mice received supranigral injection of AAV-
eGFP or AAV-hPREP, and tissue concentrations of neurotransmitters and their metabolites
were measured 5 weeks post-injection by tissue HPLC analysis. Overexpression of PREP
increased DA (h) and 5-HIAA (l) in the SN but did not have an effect on the levels of striatal
(Str) DA (a), its metabolites DOPAC (b and i) and HVA (c and j), 5-HT (d and k), striatal 5-
HIAA (d), GABA (f and m) or glutamate (GLU) (g and n). Restoring the PREP function to the
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KO mice increased the striatal DA (a) but did not have an effect on the levels of other
neurotransmitters or their metabolites. Wt-GFP n=18-21, Wt-PREP n=15-19, KO-GFP n=7-
10, KO-PREP n=3-7. Bars represent mean ± SEM, *p<0.05, **p<0.01, Student’s t-test. Values
were normalized to 100% (levels in the intact side of the brain).
Fig. 4 PREP knock-out (KO) and wild-type (Wt) littermates had the same amount of dopamine
transporters (DAT) in the striatal (Str) (a) and the nigral (SN) (b) tissue, but the levels of
phosphorylated DAT (pDAT) were enhanced in the Str of KO mice (c) measured by Western
blotting. Tyrosine hydroxylase (TH) levels were increased in the SN (e) but not in the Str (f)
of KOmice. Wt n = 6-8, and KO n = 8 (except pDAT SN n = 3-4) in each group. Bars represent
means ± SEM; *p <0.05, **p<0.01, Student´s t-test.
Fig. 5 The amount of dopamine transporter (DAT), phosphorylated DAT (pDAT) and tyrosine
hydroxylase (TH) in the striatal (Str) and the nigral (SN) tissue was measured by Western
blotting 5 weeks after a supranigral injection of AAV-hPREP or AAV-eGFP. Overexpression
of PREP increased DAT levels in the Str (a) and in the SN (b), and decreased pDAT in the Str
(c) but not in the SN (d). Amount of TH was not changed in the Str (e) or in the SN (f). DAT
and TH: n = 6-9 in each group, pDAT: n = 3-4 in each group. Bars represent mean ± SEM,
*p<0.05, Student´s t-test.
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Characterization of AAV-hPREP
To target the substantia nigra, AAV1-EF1α-hPREP or AAV1-EF1α-eGFP were given as single
injections (volume 1 µl, rate 0.2 µl/min) into the left hemisphere, 3.1 mm anterior and 1.2 mm
lateral to bregma, and 4.2 mm below the dura (stereotaxic coordinates according to Paxinos
and Franklin 1997 [1]).Tissue processing
At 2 or 4 weeks post-injection mice intended for immunohistochemistry (IHC) analysis were
deeply anesthetized with sodium pentobarbital (150 mg/kg) and transcardially perfused with
PBS followed by 4% paraformaldehyde (PFA) in PBS. Brains were post-fixed for 24-72 hours
in 4% PFA at 4 °C and transferred to a solution of 10% sucrose in PBS (pH 7.4; 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) and incubated overnight at 4 °C. On the
next day, tissues were transferred to 30% sucrose solution in PBS until brains sank to the
bottom of vial. Brains were frozen on dry ice and were kept at -80 °C until sectioning. Frozen
brain sections were sectioned as 30 µm free-floating sections on a cryostat (Leica CM3050,
Wetzlar, Germany) and kept in a cryoprotectant solution (30% ethylene glycol and 30%
glycerol in 0.5M phosphate buffer). Mice intended for PREP enzymatic activity assay were
transcardially perfused with ice-cold PBS, and thereafter brains were frozen in isopentane on
dry ice and kept at -80 °C until further analyses.PREP immunohistochemistry
PREP IHC was modiﬁed from Myöhänen et al [2]. In brief, the endogenous peroxidase activity
was inactivated with 10% methanol and 3% hydrogen peroxide (H2O2) solution in PBS (pH
7.4) for 10 min, and non-speciﬁc binding was blocked for 30 min with 10% normal goat serum
(S-1000, Vector laboratories, Peterborough, UK), after which the sections were incubated
overnight in rabbit anti-PREP primary antibody (dilution 1:500 in 1% normal serum in PBS
containing 0.5% Triton-X-100; custom made polyclonal ab, raised against PREP specific
peptide DPDSEQTKAFVEAQNK (PREP-33:48); Thermo Fisher Scientiﬁc, MA, USA). The
specificity of PREP antibody was verified by using purified porcine PREP protein and
Wt/PREP-KO mice tissue homogenates a (as described in methods, PREP antibody dilution
1:500). Subsequently, the sections were placed in goat anti-rabbit secondary antibodies for 2 h
(dilution 1:500 in 1% normal serum in PBS containing 0.5% Triton-X-100; #31460, Thermo
Fisher Scientiﬁc). The antigen–antibody complexes were identiﬁed following incubation with
0.05% 3,3′-diaminobenzidine (DAB) and 0.03% H2O2 solution. Finally, the sections were
transferred to glass slides, dehydrated in alcohol series and mounted with Depex (BDH, UK).Brain homogenization and PREP activity assay
For PREP activity assay, brains were stored at -80 °C until dissection. Cortex samples were
homogenized in 10 vol. of assay buffer (0.1 M Na–K-phosphate buffer, pH 7.0) and centrifuged
at 14,000 g at 4 °C for 20 min. The supernatants were collected and used for the activity assay
as previously described [3]. Brieﬂy, the brain homogenate was pre-incubated with assay buffer
for 30 min at 37 °C. Substrate (4 mM Suc-Gly-Pro-AMC; Bachem, Switzerland) was added to
initiate the reaction with 1 mM final concentration in the plate, and the incubation continued
for 60 min at 37 °C. The reaction was stopped with 1 M sodium acetate buffer (pH 4.2). The
formation of 7-amino-4-methylcoumarin (AMC; Bachem, Switzerland) was measured using
The Wallac 1420 Victor ﬂuorescence plate reader (PerkinElmer, Waltham, MA, USA). The
excitation and emission wavelengths were 360 and 460 nm, respectively. The protein
concentration of brain homogenate was determined using a BCA protein assay kit (Thermo
Scientiﬁc, USA).
Fast-scan cyclic voltammetry
Male mice (5-6 months of age) were decapitated and 300 µm thick coronal brain slices that
contained the cortex and the striatum were cut on a vibratome (7000 smz-2, Campden
Instruments, England) in ice-cold cutting saline containing 125 mM NaCl, 2.5 mM KCl, 26
mM NaHCO3, 0.3 mM KH2PO4, 3.3 mM MgSO4, 0.8 mM NaH2PO4, and 10 mM glucose.
Slices were allowed to recover for 1–2 hours at 32 °C in a holding chamber  with oxygen-
bubbled (95 % O2, 5 % CO2) recording saline containing 125 mM NaCl, 2.5 mM KCl, 26 mM
NaHCO3, 0.3 mM KH2PO4, 2.4 mM CaCl2, 1.3 mM MgSO4, 0.8 mM NaH2PO4, and 10 mM
glucose. In the recording chamber the slices were continuously perfused with 35 °C oxygen-
bubbled recording saline. In amphetamine (d-amphetamine hemi-sulfate, Sigma-Aldrich)
experiments the drug was added to the perfusate (5 uM) after a stable baseline of stimulated
transient peaks was reached. Fast-scan cyclic voltammetry recordings were performed with
cylindrical 5 μm carbon fiber electrodes positioned at the dorsal striatum ~50 μm below the
slice surface. Striatal slices were electrically stimulated using a bipolar stainless steel electrode
placed at a distance of ~100 μm from the recording electrode. Square pulses of 0.2 sec duration
were produced by DS3 stimulator (Digitimer Ltd, UK) that was triggered by a Master-8 pulse
generator (A.M.P.I., Israel). Stimulus magnitude was selected by plotting a current–response
curve to single pulse stimulations and selecting the minimum value that reliably produced the
maximal response. Triangular voltage ramps from −450 mV holding potential to +900 mV over
9 ms (scan rate of 300 mV/ms) were applied to the carbon fiber electrode at 100 ms intervals.
Current was recorded with an Axopatch 200B amplifier (Molecular Devices LLC, CA, USA)
filtered with 5 kHz low-pass Bessel filter and digitized at 40 kHz (ITC-18 board, InstruTech,
NY, USA). Triangular wave generation and data acquisition were controlled and the recorded
transients were characterized by a computer routine in IGOR Pro (WaveMetrics Inc,OR, USA)
[4,5]. Background-subtracted cyclic voltammograms, obtained with 1 uM DA solution (DA-
HCl), were used to calibrate the electrodes. The DA terminals were stimulated either with
single electrical pulses at 2 min intervals; paired stimulations at fixed intervals of 60, 30, 10
and 5 sec to study paired stimulation depression or by a burst stimulation of 5 pulses at 20 Hz,
to study the release probability of the terminals.
HPLC
Concentration of DA, its metabolites and 5-HIAA in dialysate was measured by HPLC with
electrochemical detection as earlier described [6] with slight modifications and the
concentration of gamma-aminobutyric acid (GABA) was measured by HPLC with
fluorescence detection as earlier described [7] with slight modifications. Tissue concentration
of DA, 5-HT and their metabolites were measured as earlier described [8] with slight
modifications.
HPLC system for determination of extracellular concentration of DA, its metabolites and 5-
HIAA consisted of a solvent delivery pump (Jasco model PU-2080 Plus, Jasco International
Co, Japan), pulse damper (SSI LP-21, Scientific Systems, State College, PA, USA), a
refrigerated autosampler (Shimadzu SIL-20AC Autosampler, Shimadzu Co, Japan), an
analytical column (Kinetex C-18 5 µm, 4.60 x 50 mm, Phemomenex Inc, USA) thermostated
by a column heater (CROCO CIL, Cluzeau Info-Labo, France and LaChrom L-7350, Merck,
Germany), an electrochemical detector (ESA Coulochem II detector, ESA Biosciences, MA,
USA) and a model 5014B microdialysis cell (ESA Biosciences, MA, USA). The mobile phase
consisted of 0.1 M NaH2PO4 buffer (Merck, Germany), 8 % (v/v) methanol (Merck), 0.2 M
ethylenediaminetetraacetic acid, 100 mg/L octanesulphonic acid, pH 4.0 and the flow rate was
1.0 mL/min. detector and a model 5014B microdialysis cell (ESA). DA was reduced with an
amperometric detector (potential -120 mV against an Ag/AgCl reference electrode) after being
oxidized with a coulometric detector (+300 mV); DOPAC and HVA were oxidized with the
coulometric detector. Injection volume was 20 µL for conventional microdialysis samples and
15 µL for no-net-flux microdialysis samples. The column temperature was kept at 45 °C. The
chromatograms were processed by AZUR chromatography data system software (Cromatek,
Essex, UK).
The HPLC system for determination of the tissue concentration of DA, 5-HT and their
metabolites consisted of a solvent delivery pump (ESA Model 582, ESA Biosciences), a
refrigerated autosampler (Shimadzu SIL-20AC, Shimadzu Corp, Japan), a microdialysis cell
(ESA Model 5014B, ESA Biosciences), an analytical column (Kinetex C-18 2.6 µm, 4.6 x 50
mm, Phenomenix Inc, USA) thermostated by a column heater (CROCO-CIL, Cluzeau Info
Lab), a pulse damper (SSI LP-21, Scientific Systems, State College, PA, USA) and an
electrochemical detector (ESA CoulArray 5600A, ESA Biosciences). The mobile phase
consisted of 0.1 M NaH2PO4 buffer, 200 mg/l of octane sulfonic acid, methanol (10 %), and
0.2 M EDTA, and the flow-rate was 1.0 µL/min Injection volume was 100 µL. The column
temperature was kept at 45 °C. Chromatograms were processed and concentrations of
monoamines calculated using CoulArray for Windows software (ESA Biosciences).
The HPLC system for determination of the extracellular concentration of GABA consisted of
a solvent delivery pump (Jasco model PU-1580 HPLC Pump, Jasco International Co, Japan)
connected to an online degasser (Jasco 3-Line Degasser, DG-980-50) and a ternary gradient
unit (Jasco LG-1580-02), a refrigerated autosampler (Shimadzu NexeraX2 SIL-30AC
Autosampler, Shimadzu Corp), an analytical column (Kinetex C-18 5 µm, 4.60 x 50 mm,
Phemomenex Inc) protected by a 0.5-mm inlet filter and thermostated by a column heater
(CROCO-CIL, Cluzeau Info-Labo, France), and a fluorescence detector (Jasco Intelligent
Fluorescence Detector model FP-1520). The wavelengths of the fluorescence detector were set
to 330 (excitation) and 450 (emission). The mobile phase consisted of 0.1 M NaH2PO4 buffer
(Merck), pH 4.9 (adjusted with Na2HPO4), 20 % (v/v) acetonitrile (Merck), and the flow-rate
was 1.2 mL/min. Automated sample derivatization was carried out using the autosampler at 8
°C. The autosampler was programmed to add 6 µL of the derivatizing reagent (3 µL of
mercaptoethanol ad 1 mL of o-phtaldialdehyde) to 15 µL of a microdialysis sample, to mix two
times, and to inject 20 µL onto the column after a reaction time of 1 min. The chromatograms
were processed by AZUR chromatography data system software (Cromatek, Essex, UK).
The tissue concentrations of GABA and glutamate were analyzed with HPLC equipped with a
fluorescence detector. Injection volume was 10 µL and mobile phase consisted 15 % (v/v)
acetonitrile in glutamate measurement, otherwise the method was similar than GABA analysis
of microdialysis samples as described above.Nigral microinjection of AAV-hPREP increases PREP activity in nigrostriatal tract
To characterize the distribution and function of viral vectors, we injected unilaterally AAV1-
EF1α-eGFP or AAV1-EF1α-hPREP above SN to Wt mice and examined the PREP enzyme
activity in striatal tissue 4 weeks post-injection (Fig. S1) and PREP expression in 2 and 4 weeks
post-injection by immunohistochemistry (Fig. S2). AAV-PREP increased PREP activity
unilaterally approximately 2-fold in striatal tissue (AAV-PREP injected vs. intact striatum F3,15
= 15.536, p = 0.00070, 1-way ANOVA, Bonferroni post-test) but AAF-GFP did not have effect
on PREP activity (Fig. S1; AAV-GFP vs. AAV-PREP F3,15 = 15.536, p = 0.00041, 1-way
ANOVA, Bonferroni post-test). PREP overexpression was observed unilaterally in SN 2 weeks
post-injection, and in both SN and striatum 4 weeks post-injection (Fig. S2).
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Fig. S1 PREP activity in the striatal tissue was measured 4 weeks after a nigral injection of
AAV-PREP. AAV-PREP increased PREP activity unilaterally (intact vs. injected striatum) and
AAV-GFP did not have an effect on PREP activity. n = 4 in each group. Bars represent mean
± SEM, ***p < 0.001, 1-way ANOVA, Bonferroni post-test.
Fig. S2 PREP expression after a unilateral nigral injection of AAV-PREP. AAV-PREP was
injected to the point above substantia nigra (SN) and PREP was stained in the striatum (Str)
and in the SN by immunohistochemistry 2 and 4 weeks post-injection. Unilateral PREP
staining can be detected in the SN 2 weeks post-injection and in both SN and Str 4 weeks post-
injection. The specificity of PREP antibody was verified by using 0.1 µg of purified porcine
PREP protein and intact (I) or AAV-PREP (PREP) injected striatal (Str) and nigral (SN) tissue
homogenates of wild-type (Wt) or PREP-KO mice (KO).
0 5 1 0 1 5 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D
is
ta
n
c
e
 t
ra
v
e
le
d
 (
c
m
)
W t
K O
B a s e lin e
D a rk  p e rio d
a
*
0 5 1 0 1 5 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D
is
ta
n
c
e
 t
ra
v
e
le
d
 (
c
m
)
W t-G F P
W t-P R E P
W t 4  w e e k sb
D a rk  p e rio d
#
# #
0 5 1 0 1 5 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D
is
ta
n
c
e
 t
ra
v
e
le
d
 (
c
m
)
K O -G F P
K O -P R E P
K O  4  w e e k sc
D a rk  p e rio d
§
§ §
W
t-G
F P
W
t-P
R E
P
K O
-G
F P
K O
-P
R E
P
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
D
is
ta
n
c
e
 t
ra
v
e
le
d
 (
c
m
)
B L
4  w k s
T o ta l d is ta n c ed
0 5 1 0 1 5 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D
is
ta
n
c
e
 t
ra
v
e
le
d
 (
c
m
)
V E H
K Y P
K Y P -2 0 4 7  s in g le  d o s ee
D a rk  p e rio d
0 5 1 0 1 5 2 0
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
D
is
ta
n
c
e
 t
ra
v
e
le
d
 (
c
m
)
V E H
K Y P
K Y P -2 0 4 7  5 -d a y  tre a tm e n tf
D a rk  p e rio d
Fig. S3 Wild-type (Wt) and PREP knock-out (KO) mice received a nigral injection of AAV-
GFP or AAV-PREP unilaterally and a 20-hour spontaneous locomotor activity test was
performed before the injections and 4 weeks after the injections. The KO mice showed
enhanced explorative behavior (a)(0-1 h: F1,22 = 7.567, *p = 0.012, repeated measures 2-way
ANOVA) but they were less active than the Wt mice during the dark period in the 2nd test (b-
c) (genotype effect 9-12 h, # vs. §: F1,18 = 3.637, p = 0.073, 16-18 h, ## vs. §§: F1,18 = 5.626,
*p = 0.029, repeated measures 2-way ANOVA). Nigrostriatal PREP overexpression (b) or
restoring PREP function (c) did not have an effect on the locomotor activity. There were no
differences in the total distance (d). Single dose (e) or 5-day treatment (f) with PREP inhibitor
(KYP-2047) did not have an effect on locomotor activity in the Wt mice. a: n = 12 in each
group, b-d: n = 5-6 in each group, e-f: n = 10-11 in each group. Bars represent mean ± SEM.
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Fig. S4 Paired-pulse and amphetamine-induced DA release in acute striatal slices in the wild-
type (Wt) and PREP knock-out (KO) mice measured by fast-scan cyclic voltammetry. Paired
pulse depression recovery (a), ratio of peak DA (b), amphetamine-induced DA efflux (c) and
DA peaks (d) were similar in the Wt and KO mice. n = 4-6 Bars represent mean ± SEM.
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Fig. S5 Paw preference was measured before and after a unilateral nigral injection of AAV-
GFP or AAV-PREP by cylinder test. GFP decreased the use of contralateral paw in the wild-
type (Wt) mice (BL vs. 4 wks *p<0.05) but overexpression of PREP did not have effect on paw
preference in the Wt mice. Restoring PREP function to the PREP knock-out (KO) mice
increased the use of contralateral paw (BL vs. 4 wks, *p<0.05) but GFP did not have an effect
on the paw preference in KO mice. n = 6-11 in each group. Bars represent mean ± SEM. Use
of contralateral paw was calculated as per cent of baseline level that was set as 100 %.
Fig. S6 Restoring PREP function to the PREP knock-out (KO) mice did not have an effect on
dopamine transporter (DAT) (a-d) or tyrosine hydroxylase (TH) (e-f). PREP function was
restored to the KO mice by a nigral injection of AAV-hPREP. Level of DAT, phosphorylated
DAT (pDAT) and TH was measured by Western blotting 5 weeks post-injection in the striatal
and nigral tissue. n = 4 in each group. Bars represent mean ± SEM.
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Fig. S7 The effect of a single dose or 5-day treatment with PREP inhibitor (KYP-2047) on
striatal neurotransmitters and metabolites was measured by striatal microdialysis. The single
dose of KYP-2047 (injection marked with arrow) did not have an effect on the level of
dopamine (DA) (a), its metabolites DOPAC (c) and HVA (e), 5-HIAA (g) or GABA (i). The
5-day treatment did not have an effect on the level of DA (b), 5-HIAA (h) or GABA (j) but
HVA level (f) was increased and there was a similar trend in DOPAC (d). n = 7-10 in each
group. Bars represent mean ± SEM, *p < 0.05, Student´s t-test.
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Fig. S8 The effect of PREP inhibition on amphetamine induced dopamine (DA) release. PREP
inhibitor (KYP-2047) did not have a statistically significant effect on amphetamine-induced
(AMPH) DA release.
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Fig. S9 A 5-day treatment with PREP inhibitor (KYP-2047) did not have an effect on the
striatal (Str) or nigral (SN) level of dopamine (DA) (a and h), its metabolites DOPAC (b and
i) and HVA (c and j), 5-HT (d and k), its metabolite 5-HIAA (e and l), GABA (f and m) or
glutamate (GLU) (g and n) in tissue HPLC analysis.
Fig. S10 PREP inhibition did not have an effect on dopamine transporter (DAT) or tyrosine
hydroxylase (TH) in the nigrostriatal tract. DAT (a-b), phosphorylated DAT (pDAT) (c-d) and
TH (e-f) in the striatal (Str) and nigral (SN) tissue were measured by Western blotting after a
5-day treatment with PREP inhibitor (KYP-2047) or vehicle. n = 5-8 in each group. Bars
represent mean ± SEM, Student´s t-test.
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